Background
Structure and characteristics
CCR9
CCL25
The expression of CCR9 in cancer
Tumors | Cell type | Methods | Expression | References |
---|---|---|---|---|
T-ALL | PBMCs (n = 21) | FCM | 91.9 % | [25] |
Melanoma | Circulating tumor cells (n = 21) | FCM | 57 % | [58] |
Melanoma | Primary specimens (n = 32) | IHC | 69.7 % | [59] |
Melanoma metastasis | Small intestinal metastases (n = 102) | QPCR | 86 % | [30] |
Mediastinal large B cell lymphomas | Lymphoid tissue (n = 22) | IHC | 90.9 %a
| [60] |
Large B cell lymphoma | Gastric extranodal diffuse lymphoma (n = 10) | IHC | 58.33 % | [61] |
Large B cell lymphoma | Gastrointestinal lymphoma (n = 41) | IHC | 66 %b
| [62] |
Ovarian cancer | Cancer tissues (n = 43) | IHC | Significantly higher | [11] |
Lung cancer | Lung biopsies (n = 50) | WB | 1.2c
| [63] |
Hepatocellular carcinoma | Cancer tissues (n = 240) | IHC | 55.8 % | [9] |
Breast cancer | Moderately differentiated cancer tissues (n = 18) | IHC | 50 % | [64] |
Poorly differentiated cancer tissues (n = 18) | IHC | >75 % | ||
Colon cancer | Adenomatous foci (n = 46) | IHC | 2.26 ± 0.06d
| [65] |
Nasopharyngeal carcinoma | Carcinoma tissues (n = 42) | IHC | 80.95 % | [66] |
The pathway of CCL25/CCR9 in cancer
CCR9 as a tumor biomarker
CCL25/CCR9 induces tumor chemoresistance
CCL25/CCR9 causes conformational change of PI3K dimers to activate PI3K/AKT pathway
CCL25/CCR9 enhances the interaction of P-gp and ERM to increase drug efflux
CCL25/CCR9 mediates STAT signaling to weaken cytotoxic effect
CCL25/CCR9 activates β-catenin to induce tumor chemoresistance
CCL25/CCR9 induces tumor metastasis
CCL25/CCR9 increases the expression of MMP2 and MMP9 to degrade collagen type IV
CCL25/CCR9 induces cancer cells polarization and microvilli absorption
Paracrine CCL25 induces tumor metastasis
CCR9 as a lymphocyte homing receptor
CCL25/CCR9 inhibits the bioactivity of PTEN gene
Pathway | Reference | |
---|---|---|
Tumor chemoresistance | PI3K/AKT | |
P-gp/ERM/F-actin | ||
STAT | Breast cancer [19] | |
β-catenin/cyclin | Pancreatic cancer [20] | |
Tumor metastasis | MMPs | |
RhoA-ROCK-MLC/ezrin | ||
Paracrine of chemokines | Pancreatic cancer [28] | |
Lymphocyte homing | ||
PTEN signaling | T-ALL [33] |